<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471169</url>
  </required_header>
  <id_info>
    <org_study_id>jinqiaowml</org_study_id>
    <nct_id>NCT03471169</nct_id>
  </id_info>
  <brief_title>Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease</brief_title>
  <official_title>Studies on the Individualized Prevention of Cerebrovascular Disease Using Study on Antithrombotic Therapy in Beijing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the therapeutic effect of individualized treatment of antiplatelet in
      secondary prevention of ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic stroke is a leading cause of disability and death worldwide. Antiplatelet treatment
      is one of treatment strategies in secondary stroke prevention for patients with
      non-cardioemoblism etiology. However, a concerning issue is that wide interindividual
      variability in P2Y12 antagonist, especially clopidogrel. The rate on-treatment high platelet
      reactivity (HPR) can be as high as in one-third of patients with standard dose of
      clopidogrel( i.e. 75mg), and HPR has been noted in those who received other P2Y12
      antagonists, such as ticagrelor and prasugrel. In the present study, we aimed to investigate
      the safety and potential therapeutic effect of individualized treatment of antiplatelet in
      secondary prevention in a cohort of patients with non-cardioembolic ischemic strokes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficient Aspirin</measure>
    <time_frame>one year</time_frame>
    <description>The value of inhibition rate of Aspirin &gt; 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficient Clopidogrel</measure>
    <time_frame>one year</time_frame>
    <description>The value of adenosine diphosphate&gt; 30%</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Platelet aggregability</measure>
    <time_frame>one year</time_frame>
    <description>The value of maximum extent of thrombosis around 31-47 mm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Cerebrovascular Disease</condition>
  <arm_group>
    <arm_group_label>Desirable TEG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undesirable TEG</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desirable TEG</intervention_name>
    <description>Change the type and dose of antithrombotic therapy and obtain desirable TEG results.
Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.</description>
    <arm_group_label>Desirable TEG</arm_group_label>
    <other_name>blood sampling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Undesirable TEG</intervention_name>
    <description>Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.</description>
    <arm_group_label>Undesirable TEG</arm_group_label>
    <other_name>blood sampling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14 years of age or older

          -  no gender aspirin or clopidogrel for ischemic cerebrovascular disease Primary or
             secondary prevention of ischemic stroke patients

          -  The researcher (or principal) signs the informed consent form

        Exclusion Criteria:

          -  Significant head trauma or stroke in the last 3 months

          -  3 months to accept intracranial, spinal surgery or other parts of large surgery

          -  In the last week there is an incurable part of the artery puncture

          -  Acute bleeding constitution, including platelet count &lt;100 × 109 / L or other
             conditions

          -  within the last 48h heparin treatment, APTT higher than the upper limit of normal
             range

          -  Oral anticoagulant: INR&gt; 1.7 or PT&gt; 15s

          -  The presence of intracranial tumors, aneurysms or arteriovenous malformations

          -  Patients with any of the following cardioembolic-related illnesses are identified:
             rheumatic mitral or aortic stenosis, prosthetic heart valves, atrial fibrillation,
             atrial flutter, sick sinus syndrome, left atrial myxoma, Open foramen ovale, left
             ventricular mural thrombus or valvular vegetation, congestive heart failure, bacterial
             endocarditis, or any other cardiovascular disease not suitable for enrollment; (as
             determined by the investigator)

          -  Severe liver and kidney dysfunction

          -  Life expectancy is less than 1 year

          -  Pregnant or lactating women

          -  Participating in other clinical studies, or have participated in other clinical
             studies within the 3 months before enrolling, or have already participated in this
             research

          -  Allergic or intolerant to aspirin or clopidogrel

          -  There are stomach lesions, such as gastritis, gastric ulcer and so on

          -  Do not want to follow-up or poor treatment compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qian Zhang, 1</last_name>
    <role>Study Director</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moli Wang, 1</last_name>
    <phone>13801234991</phone>
    <email>yifanhahahah@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qian Zhang, 2</last_name>
    <phone>13911256080</phone>
    <email>zhangqian_zq@630.sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>XuanWu hospital</name>
      <address>
        <city>Beijing</city>
        <state>Xicheng</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qian Zhang</last_name>
      <phone>13911256080</phone>
      <email>zhangqian_zq630@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antithrombotic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

